Row # | Topic | Use Case | Domains Affected | Example/Decisions | Modeling | Notes |
---|
1 | Updates from Influenza-TAUG |
| OI, IS | Hemagglutination Inhibition Assay - updates from Influenza-TAUG | Completed | |
2 | Updates from TB-TAUG v1 and v2 |
| IS | Interferon-Gamma Response Assays -updates from TB-TAUG V1 and V2 | Completed | |
3 | Antinuclear Antibody Staining |
| IS | Open-ended Findings vs Pre-specified Findings Modeling in IS | Completed | |
4 | High-Risk HPV Screening Test |
| MB | Modeling Multi-target Microbial Detection/Identification Test | Completed | |
5 | Replication Complement Lentivirus |
| MB | Replication Competent Lentivirus - Decisions | Example not needed in MB. May be Maybe needed in GF? There is a similar request to GF. | - GF team has a similar topic, need to notify Chris that the MB team has created controlled terminology for this topic and the decision
it |
6 | System Serology Data |
| IS | System Serology Examples |
|
|
7 | Updates from Influenza-TAUG |
| MB | Flu Antigen Identification Tests |
|
|
8 | HLA Allele Antibodies HLA Typing | - HLA-DPA1*01:03 Allele Antibody
- ; HLA-DPB1*04:01 Allele Antibody
- ; HLA-DPB1*04:01 Allele Antibody
- ; HLA-DPB1*04:01 Allele Antibody
- We need to move the HLA Antigen/Antibody Typing and Mismatch Examples from LB to IS. Re-evaluate examples from Kidney Transplant-TAUG (section 3.2).
| IS |
|
| - The antibodies targeting HLA antigens belong in IS, like HLA-A32 Antibody, HLA-DQB5 Antibody, but what are these
things?- allele antibodies? Need to follow up with requesters.
- Need to move the HLA Antigen/Antibody Typing data, and HLA Mismatch data from LB into IS.
- The PF data for HLA typing will be updated by the GF team, probably.
- GF team has a similar topic, need to work with Chris to see which team/domain this data fall under.
- Genomics Example Collections Planning
- Action: Inform Christine Connolly : done.
- 2023-05 (CDISC WGM): Team agree that tissue typing data should be modeled in IS. Jordan to start moving the HLA typing data from LB to IS.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|